These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3163047)

  • 1. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder.
    Malberti F; Surian M; Colussi G; Poggio F; Minoia C; Salvadeo A
    Kidney Int Suppl; 1988 Mar; 24():S184-5. PubMed ID: 3163047
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
    Wikström B; Danielson BG; Fellström B
    Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 8. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcium carbonate as a phosphate binder. One year's experience.
    Kobrin SM; Epstein SE; Goldstein SJ; Kramer MS; Raja RM
    ASAIO Trans; 1987; 33(3):518-20. PubMed ID: 3314935
    [No Abstract]   [Full Text] [Related]  

  • 10. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
    Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
    Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysis.
    Fournier A; Moriniere P
    Clin Nephrol; 1988 Jun; 29(6):319. PubMed ID: 3396236
    [No Abstract]   [Full Text] [Related]  

  • 17. [Considerations on antacid therapy].
    Holtermüller KH; Bohlen E; Castro M; Weis HJ
    Med Klin; 1977 Jul; 72(30):1229-41. PubMed ID: 329089
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis.
    Salusky IB; Coburn JW; Foley J; Nelson P; Fine RN
    J Pediatr; 1986 May; 108(5 Pt 1):767-70. PubMed ID: 3701525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.
    Leung AC; Henderson IS; Halls DJ; Dobbie JW
    Br Med J (Clin Res Ed); 1983 Apr; 286(6375):1379-81. PubMed ID: 6404468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antacid induction of phosphate depletion syndrome in renal failure.
    Abrams DE; Silcott RB; Terry R; Berne TV; Barbour BH
    West J Med; 1974 Feb; 120(2):157-60. PubMed ID: 4813797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.